Small interfering RNA (siRNA) is a class of 20-25 nucleotide-long double-stranded RNA molecules that is involved in the RNA interference (RNAi) pathway where the siRNA interferes with the expression of a specific gene. Unlike conventional low molecular drugs, siRNA does not require large-scale screenings because it can be designed only by gene sequence information. Moreover, it is expected to have fewer side effects since it can specifically inhibit particular genes. siRNA micelle are hoped to be the next generation drug, and its use has been studied for cancer, infection and age-related macular degeneration.

Although nucleic acid drugs, such as siRNA, have therapeutic efficacy, their half-life in bloodstream is very short. Stabilization utilizing a delivery system is essential to make the formulation intravenously administrable. NanoCarrier has been working with the University of Tokyo to increase stability in the bloodstream utilizing micellar nanoparticles technology.